BiondVax Pharmaceuticals Ltd.
BVXV · NASDAQ
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $2 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $1 | $2 | $2 | $4 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1 | $1 | $2 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $3 | -$11 |
| Operating Expenses | $3 | $3 | $7 | -$4 |
| Operating Income | -$3 | -$3 | -$7 | $4 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$1 | $4 | $6 | -$0 |
| Pre-Tax Income | -$4 | -$4 | -$1 | $4 |
| Tax Expense | $0 | $0 | -$6 | -$6 |
| Net Income | -$4 | -$4 | $6 | $10 |
| % Margin | – | – | – | – |
| EPS | -1.11 | -1.19 | -1.76 | 5.24 |
| % Growth | 6.7% | 32.4% | -133.6% | – |
| EPS Diluted | -1.11 | -1.19 | -1.76 | 5.24 |
| Weighted Avg Shares Out | 3 | 3 | 2 | 2 |
| Weighted Avg Shares Out Dil | 3 | 3 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $3 | $6 |
| Interest Expense | $0 | $0 | $0 | $6 |
| Depreciation & Amortization | $0 | $0 | -$2 | $6 |
| EBITDA | -$3 | -$3 | -$9 | $16 |
| % Margin | – | – | – | – |